We’re thrilled to announce a groundbreaking collaboration with Bayer to integrate Segmed’s real-world imaging data (RWiD) solution into Bayer’s AI Innovation Platform (AIIP). Together, we aim to accelerate the development of AI-powered healthcare solutions that benefit radiologists and patients alike.br br 💡 What does this mean?br With access to 100 million diverse, de-identified imaging studies via Segmed, Bayer’s platform will empower researchers, developers, and healthcare innovators to:br 🔹 Build scalable and compliant AI medical imaging toolsbr 🔹 Tackle the growing imaging workloads faced by radiologistsbr 🔹 Advance patient outcomes through cutting-edge solutionsbr br Dr. Martin Willemink, MD PhD FSCCT, our Co-founder and CEO, shares:br "Being part of an end-to-end AI developer environment has been a key vision since we founded Segmed. Through this collaboration, we’ll help healthcare organizations efficiently tap into fit-for-purpose data, ultimately improving patient outcomes."br br We sincerely thank Bayer for trusting Segmed as a partner in this journey to advance innovation in medical imaging and improve patient care worldwide.br br This partnership combines Segmed’s expertise in de-identified imaging data with Bayer’s leadership in healthcare innovation, regulatory know-how, and clinical excellence. Together, we’re driving real impact in healthcare by reducing costs, supporting radiologists, and advancing patient care.